The Intoxication Equivalency of 11-Hydroxy-Δ9-Tetrahydrocannabinol Relative to Δ9-Tetrahydrocannabinol.

IF 3.1 3区 医学 Q2 PHARMACOLOGY & PHARMACY Journal of Pharmacology and Experimental Therapeutics Pub Date : 2024-10-18 DOI:10.1124/jpet.123.001998
Ayat Zagzoog, Kenzie Halter, Alayna M Jones, Nicole Bannatyne, Josh Cline, Alexis Wilcox, Anna-Maria Smolyakova, Robert B Laprairie
{"title":"The Intoxication Equivalency of 11-Hydroxy-Δ<sup>9</sup>-Tetrahydrocannabinol Relative to Δ<sup>9</sup>-Tetrahydrocannabinol.","authors":"Ayat Zagzoog, Kenzie Halter, Alayna M Jones, Nicole Bannatyne, Josh Cline, Alexis Wilcox, Anna-Maria Smolyakova, Robert B Laprairie","doi":"10.1124/jpet.123.001998","DOIUrl":null,"url":null,"abstract":"<p><p>Δ<sup>9</sup>-Tetrahydrocannabinol (THC) is a psychoactive phytocannabinoid found in the <i>Cannabis sativa</i> plant. THC is primarily metabolized into 11-hydroxy-Δ<sup>9</sup>-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-carboxy-Δ<sup>9</sup>-tetrahydrocannabinol (COOH-THC), which may themselves be psychoactive. There is very little research-based evidence concerning the pharmacokinetics and pharmacodynamics of 11-OH-THC as an individual compound. Male C57BL/6 mice were treated with THC or 11-OH-THC via intraperitoneal injection, tail vein intravenous injection, or oral gavage, and whole-blood compound levels were measured to determine pharmacokinetic parameters [C<sub>max</sub>, time to C<sub>max</sub> (T<sub>max</sub>), elimination half-life, area under the curve, apparent volume of distribution, systemic clearance, terminal rate constant, and absolute bioavailability] while also monitoring changes in catalepsy, body temperature, and nociception. 11-OH-THC achieved a T<sub>max</sub> at 30 minutes for all routes of administration. The maximum concentration at 30 minutes was not different between intravenous and intraperitoneal routes, but the oral gavage C<sub>max</sub> was significantly lower. THC had a 10-minute time to the maximum concentration, which was the first blood collection time point, for intravenous and intraperitoneal and 60 minutes for oral gavage, with a lower C<sub>max</sub> for intraperitoneal and oral gavage compared with intravenous. When accounting for circulating compound levels and ED<sub>50</sub> responses, these data suggest that 11-OH-THC was 153% as active as THC in the tail-flick test of nociception and 78% as active as THC for catalepsy. Therefore, 11-OH-THC displayed equal or greater activity than the parent compound THC, even when accounting for pharmacokinetic differences. Thus, the THC metabolite 11-OH-THC likely plays a critical role in the bioactivity of cannabis; understanding its activity when administered directly will aid in the interpretation of future animal and human studies. SIGNIFICANCE STATEMENT: This study establishes that the primary metabolite of THC, 11-OH-THC, displays equal or greater activity than THC in a mouse model of cannabinoid activity when directly administered and even when accounting for route of administration, sex, pharmacokinetic, and pharmacodynamic differences. These data provide critical insight into the bioactivity of THC metabolites that will inform the interpretation of future in vivo cannabinoid research and represent a model for how THC consumption and metabolism may affect cannabis use in humans.</p>","PeriodicalId":16798,"journal":{"name":"Journal of Pharmacology and Experimental Therapeutics","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacology and Experimental Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1124/jpet.123.001998","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Δ9-Tetrahydrocannabinol (THC) is a psychoactive phytocannabinoid found in the Cannabis sativa plant. THC is primarily metabolized into 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (COOH-THC), which may themselves be psychoactive. There is very little research-based evidence concerning the pharmacokinetics and pharmacodynamics of 11-OH-THC as an individual compound. Male C57BL/6 mice were treated with THC or 11-OH-THC via intraperitoneal injection, tail vein intravenous injection, or oral gavage, and whole-blood compound levels were measured to determine pharmacokinetic parameters [Cmax, time to Cmax (Tmax), elimination half-life, area under the curve, apparent volume of distribution, systemic clearance, terminal rate constant, and absolute bioavailability] while also monitoring changes in catalepsy, body temperature, and nociception. 11-OH-THC achieved a Tmax at 30 minutes for all routes of administration. The maximum concentration at 30 minutes was not different between intravenous and intraperitoneal routes, but the oral gavage Cmax was significantly lower. THC had a 10-minute time to the maximum concentration, which was the first blood collection time point, for intravenous and intraperitoneal and 60 minutes for oral gavage, with a lower Cmax for intraperitoneal and oral gavage compared with intravenous. When accounting for circulating compound levels and ED50 responses, these data suggest that 11-OH-THC was 153% as active as THC in the tail-flick test of nociception and 78% as active as THC for catalepsy. Therefore, 11-OH-THC displayed equal or greater activity than the parent compound THC, even when accounting for pharmacokinetic differences. Thus, the THC metabolite 11-OH-THC likely plays a critical role in the bioactivity of cannabis; understanding its activity when administered directly will aid in the interpretation of future animal and human studies. SIGNIFICANCE STATEMENT: This study establishes that the primary metabolite of THC, 11-OH-THC, displays equal or greater activity than THC in a mouse model of cannabinoid activity when directly administered and even when accounting for route of administration, sex, pharmacokinetic, and pharmacodynamic differences. These data provide critical insight into the bioactivity of THC metabolites that will inform the interpretation of future in vivo cannabinoid research and represent a model for how THC consumption and metabolism may affect cannabis use in humans.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
11-羟基-Δ9-四氢大麻酚(11-OH-THC)相对于Δ9-四氢大麻酚(THC)的中毒当量。
Δ9-四氢大麻酚(THC)是一种精神活性植物大麻素,存在于大麻植物中。四氢大麻酚主要代谢为 11-羟基-Δ9-四氢大麻酚(11-OH-THC)和 11-去甲-9-羧基-Δ9-四氢大麻酚(COOH-THC),这两种物质本身也可能具有精神活性。有关 11-OH-THC 作为一种单独化合物的药代动力学和药效学的研究证据非常少。雄性 C57BL/6 小鼠通过静脉注射、尾静脉注射或口服灌胃(p.o)的方式接受 THC 或 11-OH-THC 治疗,测量全血化合物水平以确定药代动力学参数(Cmax、Tmax、t1/2、AUC、Vd、ClS、k 和 F),同时监测催眠、体温和痛觉的变化。在所有给药途径中,11-OH-THC 在 30 分钟内达到最大浓度。静脉注射和口服给药途径在 30 分钟内的最大浓度没有差异,但口服给药的 Cmax 明显较低。如果考虑到循环化合物水平和 ED50 反应,这些数据表明 11-OH-THC 在痛觉的尾搔试验中的活性是四氢大麻酚的 153%,在催眠中的活性是四氢大麻酚的 78%。因此,即使考虑到 PK 差异,11-OH-THC 也显示出与母体化合物 THC 相同或更高的活性。因此,四氢大麻酚代谢物 11-OH-THC 很可能在大麻的生物活性中起着至关重要的作用;了解其直接给药时的活性将有助于解释未来的动物和人体研究。意义声明 在本研究中,我们确定了在小鼠大麻素活性模型中,直接给药时 THC 的主要代谢物 11-OH-THC 显示出与 THC 相同或更高的活性,即使考虑到给药途径、性别、药代动力学和药效学差异也是如此。这些数据为了解 THC 代谢物的生物活性提供了重要信息,将为今后的大麻素研究提供参考,并为 THC 的消费和代谢如何影响人类使用大麻提供了一个模型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.90
自引率
0.00%
发文量
115
审稿时长
1 months
期刊介绍: A leading research journal in the field of pharmacology published since 1909, JPET provides broad coverage of all aspects of the interactions of chemicals with biological systems, including autonomic, behavioral, cardiovascular, cellular, clinical, developmental, gastrointestinal, immuno-, neuro-, pulmonary, and renal pharmacology, as well as analgesics, drug abuse, metabolism and disposition, chemotherapy, and toxicology.
期刊最新文献
Preclinical Evaluation of MK-8189: A Novel Phosphodiesterase 10A Inhibitor for the Treatment of Schizophrenia. Molecular mechanisms underlying amyloid beta peptide mediated upregulation of vascular cell adhesion molecule-1 in Alzheimer's disease. Clinical Development of the GluN2B-selective NMDA Receptor Inhibitor NP10679 for the Treatment of Neurologic Deficit after Subarachnoid Hemorrhage. The Influence of the Estrous Cycle on Neuropeptide S Receptor-Mediated Behaviors. Dopamine D1-Like Receptor-Mediated Insurmountable Blockade of the Reinforcing Effects of Cocaine in Rats.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1